UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of April 2020
COMMISSION
FILE Number.
000-29338
CORREVIO
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
CORREVIO
PHARMA CORP. |
|
(Registrant) |
|
|
|
Date: April 8, 2020 |
By: |
/s/
Justin Renz |
|
|
Name: Justin Renz |
|
|
Title: President and Chief Financial
Officer |
Exhibit 99.1
Correvio Obtains Interim Order For Plan
Of Arrangement
NASDAQ: CORV
TSX: CORV
VANCOUVER, April 8, 2020 /CNW/ - Correvio
Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical
company focused on commercializing hospital drugs, today announced that it has obtained an interim order from the Supreme
Court of British Columbia (the "Court") authorizing the holding of an annual general and special meeting (the
"Meeting") of the Securityholders (as defined below) and matters relating to the conduct of the Meeting.
At the Meeting, shareholders and holders of
options, restricted share units and phantom share units (collectively, the "Securityholders") will be asked to,
among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"),
involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). As announced in the Company's
press release on March 16, 2020, the Arrangement will be carried out pursuant to an arrangement agreement dated March 15, 2020
among Correvio, ADVANZ PHARMA and its subsidiary (the "Arrangement Agreement").
The Company will hold the Meeting in a virtual
only format, which will be conducted via live audio webcast at https://web.lumiagm.com/202877707 on May 15, 2020 commencing
at 10:00 a.m. (Pacific time).
Meeting materials including a notice of annual
general and special meeting of Securityholders and management information circular, are scheduled to be mailed to Securityholders
of record as of April 6, 2020 in advance of the Meeting in accordance with statutory requirements and the interim order. Upon completion
of the mailing to Securityholders, the materials for the Meeting will be filed by the Company and will be available under the Company's
SEDAR profile at www.sedar.com.
Securityholders should carefully review all
Meeting materials as they contain important information concerning the Arrangement and the rights and entitlements of the Securityholders.
About ADVANZ PHARMA
ADVANZ PHARMA operates an international specialty
pharmaceutical business with a diversified portfolio of more than 200 branded and unbranded products, and sales in more than 90
countries, and going forward, is focused on becoming the leading platform for niche established medicines, with advanced commercial
capabilities throughout Western Europe.
ADVANZ PHARMA's registered office is in Jersey,
Channel Islands. ADVANZ PHARMA operates globally through its subsidiaries in Sydney, Australia; London, England; Mumbai, India;
Dublin, Ireland; St. Helier, Jersey; and in Helsingborg Sweden.
About Correvio Pharma Corp.
Correvio Pharma Corp. is a specialty pharmaceutical
company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a
commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes
brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™
(dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio®
(ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP,
HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute
coronary syndrome. Correvio's pipeline of product candidates includes Trevyent®, a drug device combination that
is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.
Correvio is traded on the NASDAQ Capital Market
(CORV) and the Toronto Stock Exchange (CORV). For more information, please visit our web site www.correvio.com.
Correvio's Forward-Looking Statement Disclaimer
Certain statements in this news release contain
"forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking
information" under applicable Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking
statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance,
capital expenditures, financing needs and other information that may not be based on historical fact. Forward-looking statements
can often be identified by the use of terminology such as "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect", "look forward
to" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us based
on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors
we believe are appropriate.
By their very nature, forward-looking statements
involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, achievements,
events or developments to be materially different from any future results, performance, achievements, events or developments expressed
or implied by such forward-looking statements. These forward-looking statements include, but are not limited to the timing of the
Meeting, the mailing of the Meeting materials and the approval of the Arrangement by Securityholders.
Forward-looking statements are necessarily
based on estimates and assumptions made by us based on our experience and perception of historical trends, current conditions and
expected future developments, as well as other factors we believe are appropriate.
These statements reflect Correvio's current
views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered
reasonable by Correvio, are inherently subject to significant business, economic, competitive, political and social uncertainties
and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially
different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements
or information and Correvio has made assumptions and estimates based on or related to many of these factors. Such factors include,
without limitation: risks associated with the arrangement and acquisitions generally, such as the failure to satisfy the closing
conditions contained in the Arrangement Agreement, the occurrence of a material adverse effect or other events which may give the
parties a basis on which to terminate the Arrangement Agreement, the ability of the parties to complete and mail the management
information circular to be prepared in connection with the Meeting, the ability to hold the Meeting within the time frames indicated,
and the approval of the transaction by the Securityholders and the risks and uncertainties facing Correvio as discussed in the
annual report and detailed from time to time in our other filings with the Securities and Exchange Commission ("SEC")
available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. In particular, we direct your attention
to Correvio's Annual Report on Form 40-F for the year ended December 31, 2019. All of the risks and certainties disclosed in those
filings are hereby incorporated by reference in their entirety into this news release.
While Correvio makes these forward-looking
statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking
statements made in this press release. All forward-looking statements made herein are made as of the date hereof based on our current
expectations and we undertake no obligation to revise or update such forward-looking statements to reflect subsequent events, information
or circumstances, except as required by law. Investors are cautioned that forward-looking statements are not guarantees of future
performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to their inherent
uncertainty.
Correvio® and the Correvio Logo
are the proprietary trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used
under license.
Trevyent® is a trademark of SteadyMed Ltd. and used under license.
All other trademarks are the property of their respective owners.
View original content:http://www.prnewswire.com/news-releases/correvio-obtains-interim-order-for-plan-of-arrangement-301037796.html
SOURCE Correvio Pharma Corp
View original content: http://www.newswire.ca/en/releases/archive/April2020/08/c5166.html
%CIK: 0001036141
For further information: Justin Renz, President & CFO,
Correvio Pharma Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@correvio.com; Argot Partners, Michelle Carroll/Claudia Styslinger,
212.600.1902, michelle@argotpartners.com, claudia@argotpartners.com
CO: Correvio Pharma Corp
CNW 16:05e 08-APR-20
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Jul 2023 to Jul 2024